GSK Scoops Up RAPT Therapeutics

GSK chose decisive, investor-friendly ambition when agreeing to buy RAPT Therapeutics for $2.2 billion — a deal priced at $58 per share, which is at a 65.2% premium to RAPT’s previous close. That's the kind of premium that makes small-cap biotech investors briefly believe in magic again. The merger agreement was signed January 19, 2026 and GSK is set to purchase all outstanding shares of RAPT within 10 business days of signing.

GSK is paying up to expand its respiratory and immunology footprint with a long-acting approach that could potentially mean less frequent dosing than existing options — exactly the sort of "convenience moat" that can turn a good therapy into a commercially meaningful one if the clinical data cooperates. The specific prize for GSK is ozureprubart, RAPT’s experimental food-allergy therapy in Phase 2b, which GSK is buying rights to globally. Ozureprubart could be a new treatment option for about 25% of patients who are not eligible for existing therapies. GSK's global rights to sell exclude mainland China, Macau, Taiwan, and Hong Kong.

This deal is part of the company’s push to reinforce growth as it manages revenue pressure from patent expirations. With several patents expiring, GSK might lose enough revenue that it could affect its financial stability. GSK also disclosed an ownership reshuffle at ViiV Healthcare, with GSK retaining a 78.3% majority and expecting a $250 million special dividend.

Buying RAPT is meant to not only replace revenue lost due to expiring patents, but to gain customers in a sector with significant unmet medical needs. "Patient-centered treatments" are looking like the next big thing in medicine. Add in the difficulties surrounding the treatment of food allergies and it looks more and more like GSK nailed it with this one. The deal is expected to close in the first quarter of 2026, pending closing conditions are met.

Disclaimer: This content is for informational and entertainment purposes only and does not constitute financial or investment advice. The information provided may be outdated or contain inaccuracies. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions. Investing involves risk, including the potential loss of principal. Unless explicitly stated otherwise, neither Equiscreen, LLC nor its beneficial owners hold any financial interest in the companies mentioned in our articles, and we do not receive compensation for including them. Equiscreen, LLC and its beneficial owners may buy or sell securities of any company referenced in our content at any time and without prior notice, and nothing published by Equiscreen, LLC should be interpreted as a recommendation to buy, sell, or hold any security. Any paid content or income-related materials will be clearly identified as “Sponsored” or “Advertorial,” and corresponding income disclosures can be found at the bottom of the page. For additional information, please contact [email protected].

Top Gainers

Top Losers

U.S. Commodities

2234 N Federal Hwy # 1022
Boca Raton, FL 33431

(561) 264-5726